Genzyme to expand Cambridge base

Genzyme has announced plans to significantly expand its Cambridge research base.

The US biotech firm is expected to unveil details of the new, upscale Cambridge Science Park in the "not so distant future", reports Business Week.

Steve Bates, UK government relations director for the firm, told the publication that the main focus of the improved facility will be research into human monoclonal antibodies.

"The science and expertise base in the east of England makes it the ideal region in which to expand our UK research and manufacturing activities," he added.

This follows news that Genzyme plans to invest tens of millions of pounds in its Haverhill manufacturing facility.

Genzyme employs some 600 individuals throughout the UK.

It operates in manufacturing plants in Haverhill and Kent, research and development laboratories in Cambridge and a commercial office in Oxford.

Genzyme recently conducted a study which revealed that its Carticel knee implant treated pain and improved mobility for almost a decade in a number of patients.